Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Long-Term Debt Repayments: 2019-2020

  • Avidity Biosciences' Long-Term Debt Repayments was N/A to $4.0 million in Q2 2020 from the same period last year, while for Jun 2020 it was $6.1 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2020, which is 67.25% up from last year.
  • Per Avidity Biosciences' latest filing, its Long-Term Debt Repayments stood at $4.0 million for Q2 2020, which was up 469.00% from $700,000 recorded in Q1 2020.
  • In the past 5 years, Avidity Biosciences' Long-Term Debt Repayments ranged from a high of $4.0 million in Q2 2020 and a low of $700,000 during Q3 2019.
  • For the 2-year period, Avidity Biosciences' Long-Term Debt Repayments averaged around $1.5 million, with its median value being $700,000 (2020).